Other COVID-19 Interventional Studies with Macrolides:
As of May 3, 2020, the Cochrane COVID-19 Study Register lists 490
interventional studies of which 285 are randomized trials (25). In the
https://www.ncbi.nlm.nih.gov/pubmed site there are 7947 published
papers on Covid-19 (26) and at US ClinicalTrials.gov, which is a
resource provided by the U.S. National Library of Medicine, only 3
clinical trials were found for macrolides, all for azithromycin and non
for clarithromycin, but only one using azithromycin as single agent for
Covid-19 (27). This is a short description of these trials: 1.
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With
Suspected or Confirmed COVID-19 (HAHPS). This is a Phase2 randomized
Interventional study in which 300 patients will be enroll. Patients in
the Hydroxychloroquine arm will receive Hydroxychloroquine 400 mg by
mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days
(dose reductions for weight < 45 kg or GFR (glomerular
filtration rate)<50ml/min). Patients in the Azithromycin arm
will receive Azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5
(may be administered intravenously per clinician preference). If the
patient has already received azithromycin prior to randomization, the
prior doses will count toward the 5 day total. It is now recruiting. It
was First Posted : April 1, 2020, and it is done by the University of
Utah (ClinicalTrials.gov Identifier: NCT04329832) (28). 2. Azithromycin
for COVID-19. Treatment in Outpatients Nationwide (ACTION). This
individually randomized telemedicine-based trial organized by University
of California, San Francisco will evaluate the efficacy of a single dose
of 1 gr Azithromycin for prevention of progression of COVID-19 in
patients with a recent positive SARS-CoV-2 test who are not currently
hospitalized. Was First Posted on April 2, 2020 and is not still
recruiting patients. They have an estimated enrollment of 2271
participants. They propose an individually-randomized,
placebo-controlled trial to determine the efficacy of a single dose of
1gr Azithromycin for prevention of COVID-19 progression to
hospitalization (ClinicalTrials.gov Identifier: NCT04332107)(29). 3.
Azithromycin in Hospitalized COVID-19 Patients (AIC). The present study
is a randomized, double-blind, controlled, clinical trial, with the
approval of the ethics committee will be conducted on patients who have
a positive test confirming COVID-19 in Shahid Modarres Medical Education
Center and Hospital in Tehran. Patients will be randomly assigned to the
two arms of the study and after completing the course of treatment and
collecting and analyzing the necessary information from each patient,
the results of the study will be published both on this site and in the
form of an article in a reputable international journal. It is not yet
recruiting and was First Posted on April 24, 2020. Shahid Modarres
Hospital, Shahid Beheshti University of Medical Sciences and Health
Services. Tehran, Iran, Islamic Republic of, ( ClinicalTrials.gov
Identifier: NCT04359316 ) (30). No paper or study at this time was found
either in any of these sites for Clarithromycin and COVID-19 (25) (26)
(27).